1d
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their ...
Recursion Pharmaceuticals (RXRX) closed the last trading session at $8.59, gaining 20% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set ...
That brings us to Recursion Pharmaceuticals (RXRX +3.86%), a biotech company specializing in drug discovery using artificial intelligence (AI). At least one notable name in the investing world thinks ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results